

Wei-Ting Hwang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8535676/publications.pdf>

Version: 2024-02-01

124
papers

9,524
citations

126901

33
h-index

40976

93
g-index

125
all docs

125
docs citations

125
times ranked

13258
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <i>Science Translational Medicine</i> , 2015, 7, 303ra139.	12.4	1,402
2	Gene Editing of <i>CCR5</i> in Autologous CD4 T Cells of Persons Infected with HIV. <i>New England Journal of Medicine</i> , 2014, 370, 901-910.	27.0	1,227
3	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018, 24, 563-571.	30.7	1,150
4	CRISPR-engineered T cells in patients with refractory cancer. <i>Science</i> , 2020, 367, .	12.6	872
5	Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. <i>Science Translational Medicine</i> , 2012, 4, 132ra53.	12.4	555
6	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. <i>Journal of Clinical Investigation</i> , 2019, 129, 2210-2221.	8.2	513
7	Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 173.	7.1	334
8	Effects of Critical Care Nurses' Work Hours on Vigilance and Patients' Safety. <i>American Journal of Critical Care</i> , 2006, 15, 30-37.	1.6	310
9	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2016, 128, 360-370.	1.4	190
10	PSMA-targeting TGF β -insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	30.7	171
11	Effects of <i>BRCA1</i> - and <i>BRCA2</i> -Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. <i>Clinical Cancer Research</i> , 2015, 21, 211-220.	7.0	165
12	Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. <i>Nature Communications</i> , 2019, 10, 728.	12.8	149
13	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	5.0	140
14	Diversity in Graduate Medical Education in the United States by Race, Ethnicity, and Sex, 2012. <i>JAMA Internal Medicine</i> , 2015, 175, 1706.	5.1	138
15	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 2812-2815.	5.2	133
16	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. <i>Lung Cancer</i> , 2020, 139, 1-8.	2.0	92
17	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. <i>Molecular Therapy</i> , 2018, 26, 269-279.	8.2	90
18	Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN γ Combined with Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3791-3800.	7.0	77

#	ARTICLE	IF	CITATIONS
19	Screening for Family Psychosocial Risk in Pediatric Cancer: Validation of the Psychosocial Assessment Tool (PAT) Version 3. <i>Journal of Pediatric Psychology</i> , 2018, 43, 737-748.	2.1	77
20	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. <i>Blood</i> , 2018, 132, 298-298.	1.4	73
21	Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2354-2361.	7.0	70
22	Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy. <i>JAMA Surgery</i> , 2018, 153, e174591.	4.3	68
23	Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 896-909.	3.4	64
24	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 246-253.	1.4	62
25	Lin-28 Homologue A (LIN28A) Promotes Cell Cycle Progression via Regulation of Cyclin-dependent Kinase 2 (CDK2), Cyclin D1 (CCND1), and Cell Division Cycle 25 Homolog A (CDC25A) Expression in Cancer. <i>Journal of Biological Chemistry</i> , 2012, 287, 17386-17397.	3.4	60
26	Underrepresentation of Women and Minorities in the United States IR Academic Physician Workforce. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1837-1844.e2.	0.5	59
27	I Can't Breathe: The Continued Disproportionate Exclusion of Black Physicians in the United States Radiation Oncology Workforce. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 856-863.	0.8	52
28	Female Representation in the Academic Oncology Physician Workforce: Radiation Oncology Losing Ground to Hematology Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 31-33.	0.8	51
29	Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. <i>Cancer</i> , 2017, 123, 794-801.	4.1	51
30	Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. , 2020, 8, e000974.		49
31	Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. <i>Carcinogenesis</i> , 2016, 37, 177-187.	2.8	44
32	High Resolution Magnetic Resonance Imaging for Characterization of the Neuroligin-3 Knock-in Mouse Model Associated with Autism Spectrum Disorder. <i>PLoS ONE</i> , 2014, 9, e109872.	2.5	36
33	Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 669-676.	1.2	36
34	No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. <i>Cancer</i> , 2017, 123, 1324-1332.	4.1	35
35	Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 309-318.	2.5	34
36	Exercise-Induced Dose-Response Alterations in Adiponectin and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1195-1200.	2.5	33

#	ARTICLE	IF	CITATIONS
37	Association between mesothelioma and non-occupational asbestos exposure: systematic review and meta-analysis. <i>Environmental Health</i> , 2018, 17, 90.	4.0	33
38	Factors that predict for representation of women in physician graduate medical education. <i>Medical Education Online</i> , 2019, 24, 1624132.	2.6	33
39	CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. <i>Cell Reports Medicine</i> , 2021, 2, 100394.	6.5	29
40	Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2020, 25, e381-e385.	3.7	27
41	Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	3.3	25
42	SECTM1 Produced by Tumor Cells Attracts Human Monocytes via CD7-Mediated Activation of the PI3K Pathway. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1108-1118.	0.7	24
43	Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 504-510.	1.9	24
44	Dynamic Contrast-Enhanced MRI-Derived Intracellular Water Lifetime ($T_{1\rho}$): A Prognostic Marker for Patients with Head and Neck Squamous Cell Carcinomas. <i>American Journal of Neuroradiology</i> , 2018, 39, 138-144.	2.4	24
45	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. <i>Blood</i> , 2019, 134, 1873-1875.	1.4	24
46	Comparing GPS, Log, Survey, and Accelerometry to Measure Physical Activity. <i>American Journal of Health Behavior</i> , 2016, 40, 123-131.	1.4	23
47	Assessing Interpersonal and Communication Skills in Radiation Oncology Residents: A Pilot Standardized Patient Program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1129-1135.	0.8	22
48	The Synthetic Lignan Secoisolariciresinol Diglucoside Prevents Asbestos-Induced NLRP3 Inflammasome Activation in Murine Macrophages. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-14.	4.0	22
49	Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL. <i>Journal of Clinical Oncology</i> , 2016, 34, 3009-3009.	1.6	22
50	Diastolic dysfunction in tetralogy of Fallot: Comparison of echocardiography with catheterization. <i>Echocardiography</i> , 2018, 35, 1641-1648.	0.9	21
51	Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. <i>Cancer</i> , 2016, 122, 2350-2355.	4.1	20
52	Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size. <i>Journal of Virology</i> , 2016, 90, 10436-10445.	3.4	20
53	A mineralogical and chemical investigation of road dust in Philadelphia, PA, USA. <i>Environmental Science and Pollution Research</i> , 2020, 27, 14883-14902.	5.3	20
54	Women In Steady Exercise Research (WISER) Sister: Study design and methods. <i>Contemporary Clinical Trials</i> , 2015, 41, 17-30.	1.8	19

#	ARTICLE	IF	CITATIONS
55	Adjuvant Radiation for Locally Advanced Bladder Cancer? A Question Worth Asking. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1040-1042.	0.8	19
56	Outcomes in Patients With Non-“small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. <i>Clinical Lung Cancer</i> , 2021, 22, 58-66.e3.	2.6	19
57	Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting. <i>Cancer</i> , 2019, 125, 4278-4293.	4.1	18
58	SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments. <i>JAMA Oncology</i> , 2022, 8, 164.	7.1	15
59	Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 703-706.	0.8	14
60	Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy. <i>Advances in Radiation Oncology</i> , 2016, 1, 325-332.	1.2	14
61	Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-“Small-cell Lung Cancer: Results of a Phase II Study. <i>Clinical Lung Cancer</i> , 2018, 19, 157-162.	2.6	14
62	Validation of the Spanish Version of the Psychosocial Assessment Tool (PAT) in Pediatric Cancer. <i>Journal of Pediatric Psychology</i> , 2018, 43, 1104-1113.	2.1	14
63	Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy. <i>Acta Oncologica</i> , 2018, 57, 1506-1514.	1.8	13
64	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 127, 25-33.	2.0	13
65	Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. <i>Scientific Reports</i> , 2021, 11, 9984.	3.3	13
66	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1863-1863.	1.4	13
67	Low apolipoprotein A-I levels in Friedreich’s ataxia and in frataxin-deficient cells: Implications for therapy. <i>PLoS ONE</i> , 2018, 13, e0192779.	2.5	13
68	A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2076-2086.	2.3	11
69	Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis-Related Liver Disease. <i>Liver Transplantation</i> , 2018, 24, 1665-1672.	2.4	11
70	A randomized clinical trial comparing adjuvant radiation versus chemo-RT versus chemotherapy alone after radical cystectomy for locally advanced bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 356-356.	1.6	11
71	Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Cancer Medicine</i> , 2023, 12, 189-199.	2.8	11
72	Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center. <i>Advances in Radiation Oncology</i> , 2017, 2, 132-139.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Acute Hospital Encounters in Cancer Patients Treated With Definitive Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 935-944.	0.8	10
74	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. <i>Blood</i> , 2019, 134, 49-49.	1.4	10
75	Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9022-9022.	1.6	10
76	Copper Oxide Nanoparticle-Induced Acute Inflammatory Response and Injury in Murine Lung Is Ameliorated by Synthetic Secoisolariciresinol Diglucoside (LGM2605). <i>International Journal of Molecular Sciences</i> , 2021, 22, 9477.	4.1	9
77	Air pollution and lung cancer survival in Pennsylvania. <i>Lung Cancer</i> , 2022, 170, 65-73.	2.0	9
78	Evaluating the effects of design parameters on the performances of phase I trial designs. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100379.	1.1	8
79	A phase I trial of cyclosporine for hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, .	5.0	8
80	Geographic Differences in Lung Cancer Incidence: A Study of a Major Metropolitan Area within Southeastern Pennsylvania. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9498.	2.6	7
81	CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL. <i>Blood</i> , 2021, 138, 469-469.	1.4	7
82	Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100301.	1.1	7
83	Environmental exposomics and lung cancer risk assessment in the Philadelphia metropolitan area using ZIP code—level hazard indices. <i>Environmental Science and Pollution Research</i> , 2021, 28, 31758-31769.	5.3	6
84	Effects of BRCA1/2 on Ovarian and Breast Cancer Survival—Response. <i>Clinical Cancer Research</i> , 2015, 21, 3807-3807.	7.0	5
85	Framework for assessment and phytoremediation of asbestos-contaminated sites. <i>Environmental Science and Pollution Research</i> , 2017, 24, 25912-25922.	5.3	5
86	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 95-102.	2.9	5
87	Radiation activates myeloperoxidase (MPO) to generate active chlorine species (ACS) via a dephosphorylation mechanism - inhibitory effect of LGM2605. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129548.	2.4	5
88	The aryl hydrocarbon receptor mediates sex ratio distortion in the embryos sired by TCDD-exposed male mice. <i>Reproductive Toxicology</i> , 2020, 94, 75-83.	2.9	5
89	Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 217-226.	2.5	4
90	Differential elemental uptake in three pseudo-metallophyte C4 grasses in situ in the eastern USA. <i>Plant and Soil</i> , 2017, 416, 149-163.	3.7	4

#	ARTICLE	IF	CITATIONS
91	Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1545-1552.	2.8	4
92	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. <i>Blood</i> , 2020, 136, 30-32.	1.4	4
93	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. <i>Clinical Cancer Research</i> , 2022, 28, 3940-3949.	7.0	4
94	Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 45-53.	2.5	3
95	Risk factors for 30-day readmission in adults hospitalized for pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-14.	1.7	3
96	Autologous CD4 ⁺ Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. <i>Molecular Therapy</i> , 2021, 29, 626-635.	8.2	3
97	Randomized trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced bladder cancer after radical cystectomy. <i>Journal of Clinical Oncology</i> , 2019, 37, 4507-4507.	1.6	3
98	Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients. <i>Blood</i> , 2021, 138, 1757-1757.	1.4	3
99	A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2021, 138, 2512-2512.	1.4	3
100	Identification of spatio-temporal clusters of lung cancer cases in Pennsylvania, USA: 2010-2017. <i>BMC Cancer</i> , 2022, 22, 555.	2.6	3
101	Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 395-401.	0.9	2
102	Understanding the predictive value of continuous markers for censored survival data using a likelihood ratio approach. <i>BMC Medical Research Methodology</i> , 2019, 19, 108.	3.1	2
103	Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 9599-9599.	1.6	2
104	Prospective trial of adjuvant therapy after radical cystectomy for locally advanced bladder cancer: Analysis of the squamous cell carcinoma subgroup. <i>Journal of Clinical Oncology</i> , 2020, 38, 524-524.	1.6	2
105	Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, e301-e309.	2.6	2
106	Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 524-529.	1.9	1
107	Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure. <i>Biomarkers in Medicine</i> , 2017, 11, 547-556.	1.4	1
108	Reply to Neutrophil-to-Lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. <i>Cancer</i> , 2017, 123, 3856-3856.	4.1	1

#	ARTICLE	IF	CITATIONS
109	Optimal cutoffs for continuous biomarkers for survival data under competing risks. Communications in Statistics Part B: Simulation and Computation, 2019, 48, 1330-1345.	1.2	1
110	Incorporation of plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 14-14.	1.6	1
111	A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.. Journal of Clinical Oncology, 2012, 30, 262-262.	1.6	1
112	Gene signature of antigen processing and presentation machinery (APM) as highly predictive of response to checkpoint blockade in lung cancer and melanoma.. Journal of Clinical Oncology, 2020, 38, 3121-3121.	1.6	1
113	Real-world outcomes after second-line treatment in non-small cell lung cancer (NSCLC) patients treated with immunotherapy.. Journal of Clinical Oncology, 2020, 38, e21620-e21620.	1.6	1
114	Rapid prediction of stem cell mobilization using volume and conductivity data from automated hematology analyzers. Transfusion, 2018, 58, 330-338.	1.6	0
115	OUP accepted manuscript. Journal of Pediatric Psychology, 2022, , .	2.1	0
116	Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort.. Journal of Clinical Oncology, 2014, 32, 297-297.	1.6	0
117	Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy.. Journal of Clinical Oncology, 2015, 33, 398-398.	1.6	0
118	Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer.. Journal of Clinical Oncology, 2015, 33, 347-347.	1.6	0
119	Cyclin-dependent kinase 4/6 inhibition for the treatment of mature teratoma germ cell tumor: Long-term follow-up of a phase II study.. Journal of Clinical Oncology, 2016, 34, 474-474.	1.6	0
120	Neutrophil-to-lymphocyte ratio as a prognostic biomarker in bladder cancer: A REMARK-guided secondary analysis of SWOG 8710.. Journal of Clinical Oncology, 2016, 34, 361-361.	1.6	0
121	Acute hospitalizations in cancer patients treated with definitive radiotherapy: A retrospective cohort study with implications for an urgent care clinic.. Journal of Clinical Oncology, 2016, 34, 312-312.	1.6	0
122	Impact of breast magnetic resonance imaging (MRI) on long-term outcome after breast conservation therapy (BCT).. Journal of Clinical Oncology, 2016, 34, 1053-1053.	1.6	0
123	Prospective trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced bladder cancer after radical cystectomy.. Journal of Clinical Oncology, 2020, 38, 515-515.	1.6	0
124	Treatment patterns and outcomes in <i>ALK</i> or <i>ROS1</i> altered NSCLC: An ATOMIC Registry Study.. Journal of Clinical Oncology, 2022, 40, 9077-9077.	1.6	0